Remission and recovery in lurasidone-treated patients with bipolar depression: post-hoc analysis of a 6-week, placebo-controlled trial followed by a 6-month extension

被引：0
|
作者：
Loebel, A. [1 ]
Siu, C. [2 ]
Rajagopalan, K. [3 ]
Pikalov, A. [4 ]
Cucchiaro, J. [5 ]
Ketter, T. [6 ]
机构：
[1] Sunovion Pharmaceut Inc, Ft Lee, NJ USA
[2] COS Consulting, Data Sci & Analyt, Montreal, PQ, Canada
[3] Sunovion Pharmaceut Inc, Hlth Econ & Outcomes Res, Marlborough, MA USA
[4] Sunovion Pharmaceut Inc, Clin Dev & Med Affairs, Ft Lee, NJ USA
[5] Sunovion Pharmaceut Inc, Clin Operat, Ft Lee, NJ USA
[6] Stanford Univ, Psychiat & Behav Sci, Stanford, CA 94305 USA
来源：
BIPOLAR DISORDERS | 2015年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [41] Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study
    Patel, Preeya J.
    Weidenfeller, Christian
    Jones, Andrew P.
    Nilsson, Jens
    Hsu, Jay
    NEUROLOGY AND THERAPY, 2021, 10 (01) : 121 - 147
  • [42] Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: pooled analysis of double-blind, placebo-controlled 6-week studies
    Costamagna, I.
    Calisti, F.
    Hsu, J.
    Tocco, M.
    Pikalov, A.
    Goldman, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S473 - S474
  • [43] Efficacy and safety of lurasidone in schizophrenia: pooled analysis of European results from double-blind, placebo-controlled 6-week studies
    Calisti, Fabrizio
    Cattaneo, Agnese
    Calabrese, Mariangela
    Mao, Yongcai
    Tocco, Michael
    Pikalov, Andrei
    Goldman, Robert
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2022, 37 (05) : 215 - 222
  • [44] Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension
    Harvey, Philip D.
    Siu, Cynthia O.
    Hsu, Jay
    Cucchiaro, Josephine
    Maruff, Paul
    Loebel, Antony
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (11) : 1373 - 1382
  • [45] The efficacy of lurasidone on PANSS subscales in adolescent patients with schizophrenia: Results from a 6-week, double-blind, placebo-controlled, multicenter study
    Correll, C.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2017, 41 : S90 - S91
  • [46] A 6-MONTH, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND TRIAL OF ZIPRASIDONE PLUS A MOOD STABILIZER IN SUBJECTS WITH BIPOLAR I DISORDER
    Vieta, E.
    Bowden, C.
    Ice, K.
    Gurtovaya, O.
    Schwartz, J.
    Wang, P.
    EUROPEAN PSYCHIATRY, 2009, 24
  • [47] Effect of Lurasidone Dose on Recurrence Prevention in Patients With Bipolar I Disorder: Post Hoc Analysis of a Placebo-Controlled Randomized Withdrawal Study
    Frye, Mark
    Tsai, Joyce
    Mao, Yongcai
    Pikalov, Andrei
    Loebel, Antony
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S525 - S526
  • [48] Efficacy and Safety of Cordyceps militaris as an Adjuvant to Duloxetine in the Treatment of Insomnia in Patients With Depression: A 6-Week Double- Blind, Randomized, Placebo-Controlled Trial
    Zhou, Jiaojiao
    Chen, Xu
    Xiao, Le
    Zhou, Jingjing
    Feng, Lei
    Wang, Gang
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [49] Home-based, Remotely Supervised, 6-Week tDCS in Patients With Both MCI and Depression: A Randomized Double-Blind Placebo-Controlled Trial
    Kim, Jiheon
    Park, Seungchan
    Kim, Hansol
    Roh, Daeyoung
    Kim, Do Hoon
    CLINICAL EEG AND NEUROSCIENCE, 2024, 55 (05) : 531 - 542
  • [50] Bifeprunox prolongs time to deterioration in patients with stable schizophrenia: A more stringent post hoc analysis of a 6-month, randomized, double-blind, placebo-controlled study
    Casey, Daniel E.
    Bourin, Michel
    Debelle, Marc
    Heisterberg, Jens
    Josiassen, Mette Krog
    Ostergard, Jette Buch
    Shapira, Nathan A.
    Yeung, Paul P.
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 80S - 81S
12345